Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the class of hydroquinolones. It has a chemical formula of C13H13N3O and an average molecular weight of approximately 227.26 g/mol. The drug acts as an inhibitor targeting serine/threonine-protein kinase Chk1 (Checkpoint kinase 1), which plays a role in cell cycle regulation and DNA damage response. It is classified as experimental with no approved indications or detailed developer/manufacturer information publicly available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-ethyl-3-methyl-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one.